Thursday, 15 November 2018

Enesi Pharma, Sementis enter into R&D collaboration

05 November 2018 | News

The collaboration is focused on the development and evaluation of solid dose versions of Sementis' lead peanut hypoallergy vaccine and their single vectored chikungunya/Zika vaccine candidates for administration via Enesi Pharma's ImplaVax technology.

Image credit- discovery.rsml.nl

Image credit- discovery.rsml.nl

UK based Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products, and Sementis, an Australian biotechnology company developing innovative vaccine candidates for the prevention of allergies and infectious diseases, have entered into a collaborative agreement.

The collaboration is focused on the development and evaluation of solid dose versions of Sementis' lead peanut hypoallergy vaccine and their single vectored chikungunya/Zika vaccine candidates for administration via Enesi Pharma's ImplaVax technology.

ImplaVax is an innovative and proprietary needle-free solid dose implant and device technology for subcutaneous vaccination. Data to date demonstrate that ImplaVax-enabled vaccines can deliver superior immune responses compared to standard injection protocols among other benefits such as safety, ease of use, reliability and stability.

Sementis' single vectored vaccine for chikungunya/Zika virus infection is promising with extensive proof-of-concept studies in mice demonstrating the effectiveness of the vaccine in protecting against Zika and chikungunya from a single vaccination shot.

 

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Survey Box

Are New-Age Healthcare Consumers In Asia Embracing Technology?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls